Proteomics analysis of malignant pleural effusion
Research type
Research Study
Full title
Proteomics analysis of malignant pleural effusion for prediction of favourable prognosis and pleurodesis success (PROMISE)
IRAS ID
163119
Contact name
Najib/M Rahman
Contact email
Sponsor organisation
Research & Development Department - Oxford University Hospitals NHS Foundation Trust
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
The majority of cancers metastasise to the pleural space, an area between the layers of tissue that line the lungs and the chest cavity. Cancer installation to the pleura provokes fluid production and accumulation, which is known as malignant pleural effusion (MPE). MPE signals incurability, shortened life expectancy (3-12months), and severely compromised quality of life in cancer patients. Available treatments can halt fluid production in approximately only 70% of patients. Currently there are not known predictors of good prognosis not therapeutic success in MPE.
Our research proposal will for the first time, use a break-through biological technique in order to identify proteins that predict prognosis and therapeutic success in patients with MPE. We will analyse a database of patients obtained by a previous clinical trial (TIME-2 study) from our department. It consists of serial pleural fluids collected from different cancers (lung, breast, ovarian, mesothelioma) which all have been metastasised in pleural space. We will categorise the patients according to their prognosis and treatment and perform a new biological technique called proteomics analysis to determine the protein expression in the pleural fluid. The results of this analysis will allow determining the proteins profile of patients with favourable prognosis and treatment response. We will validate the biomarkers in a different study database (TIME-1 study) to strengthen our results.
The ultimate aim of our study is to redefine therapy in a patient centered model by using protein expression in the pleural fluid.
The study will be conducted in Oxford University Hospitals Trust & University of Oxford research facilities. The study will last for 1 year and there are no interventions for the participants of the study as the investigators will only analyse the stored samples in Oxford Biobank.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
15/SC/0186
Date of REC Opinion
24 Mar 2015
REC opinion
Favourable Opinion